Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Absci Corporation ABSI NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
40/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$6.16
+94.3%

Absci Corporation (ABSI) is a Biotechnology company in the Healthcare sector, currently trading at $3.17. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is ABSI = $6 (+94.3% upside).

Valuation: ABSI trades at a trailing Price-to-Earnings (P/E) of -3.9 (S&P 500 average ~25).

Financials: revenue is $3M, -19.8%/yr average growth. Net income is $115M (loss), growing at -3.5%/yr. Net profit margin is -4113.7% (negative). Gross margin is -319.4% (-192.6 pp trend).

Balance sheet: total debt is $5M against $189M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 6.57 (strong liquidity). Debt-to-assets is 2.5%. Total assets: $216M.

Analyst outlook: 9 / 12 analysts rate ABSI as buy (75%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 0/100 (Fail), Future 85/100 (Pass), Income 10/100 (Fail).

$6.16
▲ 94.32% Upside
Average Price Target
Based on 12 Wall Street analysts offering 12-month price targets for Absci Corporation, the average price target is $6.16, with a high forecast of $8.00, and a low forecast of $4.32.
Highest Price Target
$8.00
Average Price Target
$6.16
Lowest Price Target
$4.32

ABSI SharesGrow Score Overview

55/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 85/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ABSI

✓
VALUE Pass
100/100
ABSI trades at a trailing Price-to-Earnings (P/E) of -3.9 (S&P 500 average ~25). Forward PEG -15.55 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $6, implying +89.3% from the current price $3. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
ABSI: -19.8%/yr revenue is, -3.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet ABSI: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 6.57 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
✓
FUTURE Pass
85/100
Analyst outlook: 9 / 12 analysts rate ABSI as buy (75%). Analyst consensus target is $6 (+89.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
ABSI: Net profit margin is -4113.7%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range2.011-5.228
Volume2.76M
Avg Volume (30D)3.63M
Market Cap$485.08M
Beta (1Y)2.01
Share Statistics
EPS (TTM)-0.84
Shares Outstanding$136.78M
IPO Date2021-07-22
Employees156
CEOSean McClain
Financial Highlights & Ratios
Revenue (TTM)$2.8M
Gross Profit$-8.94M
EBITDA$-112.98M
Net Income$-115.18M
Operating Income$-124.72M
Total Cash$144.29M
Total Debt$5.3M
Net Debt$-14.72M
Total Assets$216.3M
Price / Earnings (P/E)-3.8
Price / Sales (P/S)173.24
Analyst Forecast
1Y Price Target$6.16
Target High$8.00
Target Low$4.32
Upside+94.3%
Rating ConsensusBuy
Analysts Covering12
Buy 75% Hold 8% Sell 17%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS00091E1091

Price Chart

Track all markets on TradingView
ABSI
Absci Corporation ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
2.01 52WK RANGE 5.23

People Also View

RLAY
RLAY
Relay Therapeutics, Inc.
$15.49
+5.02%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.47
+0.05%
 RXRX
RXRX
Recursion Pharmaceuticals, Inc.
$3.75
+5.93%
 VECT
VECT
VectivBio Holding AG
$16.87
+0.12%
 SANA
SANA
Sana Biotechnology, Inc.
$3.44
-1.15%
 ICVX
ICVX
Icosavax, Inc.
$15.31
-0.91%
 EXAI
EXAI
Exscientia plc
$4.84
+0.00%
 ZURA
ZURA
Zura Bio Limited
$5.69
-0.52%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message